Skip to main content

Advertisement

SpringerLink
Log in

Heterogeneous distribution of PD-L1 expression in the IASLC/ATS/ERS classification of lung adenocarcinoma

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

PD-L1 expression in tumor cells can predict the efficacy of PD-1/PD-L1 inhibitors and prognosis in patients. However, the correlation between the PD-L1 expression and the novel lung adenocarcinoma classification are obscure.

Methods

94 lung adenocarcinoma cases were reviewed in the Third Affiliated Hospital of Soochow University from January to December 2019. PD-L1 (DAKO 22C3) was used to test the PD-L1 expression in lung cancer tissue.

Result

TPS was used to interpret the PD-L1 expression. The negative, low positive and high positive of PD-L1 were 52 cases (55.30%), 29 cases (30.90%) and 13 cases (13.80%). The subtype ratio of acinar, lepidic and solid in adenocarcinoma were correlation with the PD-L1 TPS (r =  − 0.37, P < 0.001; r =  − 0.22, P = 0.013; r = 0.68, P < 0.001). The results of χ2 test showed the PD-L1 expression had the significant difference with gender (P = 0.027), age (P = 0.018), smoking history (P = 0.021), lymph node metastasis (P = 0.001), TNM stage (P = 0.002), acinar structure (P = 0.017) and solid structure (P < 0.001). Multi-factor linear regression results suggested that solid structure, TNM stage and smoking history were associated with PD-L1 expression (P < 0.05). The solid structure showed more capability to PD-L1 expression (β = 0.398).

Conclusion

PD-L1 expression was heterogeneity in lung adenocarcinoma. The solid structure, TNM stage and smoking history were correlation to up-regulation of PD-L1 expression, and solid structure was the most importance factor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

All data generated or analyzed during this study are included in this published article.

Abbreviations

NSCLC :

Non-small cell lung cancer

ADC :

Lung adenocarcinoma

IASLC :

International association for the study of lung cancer

AST :

American thoracic society

ERS :

European respiratory society

PD-1/PD-L1 :

Programmed cell death protein 1/Programmed cell death 1 ligand 1

TPS :

Tumor proportion score

References

  1. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424

    Google Scholar 

  2. Wei KR, Yu X, Zheng RS et al (2010) (2014) Incidence and mortality of liver cancer in China. Chin J Cancer 33(8):388–394

    Google Scholar 

  3. Schwaederle MC, Patel SP, Husain H et al (2017) Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clin Cancer Res 23(17):5101–5111

    Article  CAS  Google Scholar 

  4. Hsu FT, Liu HS, Ali AAA et al (2018) Assessing the selective therapeutic efficacy of superparamagnetic erlotinib nanoparticles in lung cancer by using quantitative magnetic resonance imaging and a nuclear factor kappa-B reporter gene system. Nanomedicine 14(3):1019–1031

    Article  CAS  Google Scholar 

  5. Ooki A, Dinalankara W, Marchionni L et al (2018) Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma. Oncogene 37(45):5967–5981

    Article  CAS  Google Scholar 

  6. Travis WD, Brambilla E, Noguchi M et al (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6(2):244–285

    Article  Google Scholar 

  7. Reck M, Rodríguez-Abreu D, Robinson AG et al (2019) Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 37(7):537–546

    Article  CAS  Google Scholar 

  8. Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer–immune set point. Nature 541(7637):321–330

    Article  CAS  Google Scholar 

  9. Ancevski Hunter K, Socinski MA, Villaruz LC (2017) PD-L1 Testing in guiding patient selection for PD-1/PD-L1 inhibitor therapy in lung cancer. Mol Diagn Ther 22(1):1–10

    Article  Google Scholar 

  10. Hirsch FR, McElhinny A, Stanforth D et al (2017) PD-L1 Immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 12(2):208–222

    Article  Google Scholar 

  11. Neuman T, London M, Kania-Almog J et al (2016) A harmonization study for the use of 22C3 PD-L1 immunohistochemical staining on ventana’s platform. J Thorac Oncol 11(11):1863–1868

    Article  Google Scholar 

  12. Mok TSK, Wu YL, Kudaba I et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393(10183):1819–1830

    Article  CAS  Google Scholar 

  13. Pawelczyk K, Piotrowska A, Ciesielska U et al (2019) Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. Int J Mol Sci 20(4):824

    Article  CAS  Google Scholar 

  14. Yoshiya T, Mimae T, Tsutani Y et al (2016) Prognostic role of subtype classification in small-sized pathologic N0 invasive lung adenocarcinoma. Ann Thorac Surg 102(5):1668–1673

    Article  Google Scholar 

  15. Xu Y, Zhu C, Qian W et al (2017) Comprehensive study of mutational and clinicopathologic characteristics of adenocarcinoma with lepidic pattern in surgical resected lung adenocarcinoma. J Cancer Res Clin Oncol 143(1):181–186

    Article  CAS  Google Scholar 

  16. Shimoji M, Shimizu S, Sato K et al (2016) Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). Lung Cancer 98:69–75

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This study was supported in part by the Young Talent Development Plan of Changzhou Health Commission (CZQM2020040).

Author information

Authors and Affiliations

  1. Department of Pathology, The Third Affiliated Hospital of Soochow University, Juqian Road No.185, Changzhou, Jiangsu, 213003, People’s Republic of China

    Dachuan Zhang, Xie Gao, Zhantao Yan & Qing Li

  2. Department of Oncology, The Third Affiliated Hospital of Soochow University, Juqian Road No.185, Changzhou, Jiangsu, 213003, People’s Republic of China

    Wenting He

Authors
  1. Dachuan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xie Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhantao Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenting He
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DC Zhang and WT He participated in the design of the study and performed the statistical analysis. ZT Yan, and X Gao participated in the Immunohistochemical staining. DC Zhang and Q Li drafted the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Wenting He or Qing Li.

Ethics declarations

Conflict of interest

These authors declare that they have no competing interests.

Ethical approval

This study protocol was approved by the Ethics Committee of Soochow University and conducted in accordance with the Declaration of Helsinki.

Informed consent

Informed consent was obtained from patients before enrollment in this study.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, D., Gao, X., Yan, Z. et al. Heterogeneous distribution of PD-L1 expression in the IASLC/ATS/ERS classification of lung adenocarcinoma. Int J Clin Oncol 27, 105–111 (2022). https://doi.org/10.1007/s10147-021-02035-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-021-02035-2

Keywords

Search

Navigation